



**EXPEDITED PROCEDURE
RESPONSE UNDER 37 C.F.R. § 1.116
GROUP ART UNIT: 1632**

PATENT
Customer Number 22,852
Attorney Docket No. 0288.1129

RECEIVED
SEP 09 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jean-Francois DEDIEU et al.

Serial No.: 09/654,223

Filed: August 31, 2000

)
)
)
)
)

Group Art Unit: 1632

Examiner: D. Nguyen

Mail Stop AF

For: RECOMBINANT ADENOVIRUSES FOR GENE THERAPY IN CANCERS

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

AMENDMENT AND RESPONSE TO PAPER NO. 9

In response to the Final Office Action dated March 24, 2003 (Paper No. 9), the period for response having been extended by a petition for extension of time and fee filed concurrently herewith, and pursuant to 37 C.F.R. § 1.173(b), please enter the following amendment:

IN THE SPECIFICATION:

Column 1, lines 4-5, first paragraph:

This application is a reissue application of U.S. Patent No. 5,837,531, which issued on November 17, 1998, from U.S. Application S.N. 08/646,246, which is a national phase application under 35 U.S.C. 371 of PCT/FR 94/01284, filed Nov. 07, 1994, which claims priority to FR 93 13766 filed on November 18, 1993.